Financial & competing interests disclosure
Funding from the National Health and Medical Research Council of Australia (Fellowship 1024620 to EF Lee and Project Grant 1002227 to WD Fairlie) is gratefully acknowledged. The Walter and Eliza Hall Institute receives milestone payments for the development of BH3-mimetics for cancer therapy from Genentech and AbbVie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Additional information
Funding
Funding from the National Health and Medical Research Council of Australia (Fellowship 1024620 to EF Lee and Project Grant 1002227 to WD Fairlie) is gratefully acknowledged. The Walter and Eliza Hall Institute receives milestone payments for the development of BH3-mimetics for cancer therapy from Genentech and AbbVie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.